News & Media
Check out the latest news on MygoGenesis™ and its constellation of companies.
MygoGenesis Appoints Deborah Zimmermann as President and Chief Executive Officer
Advancing Commercialization of AmeboGenesis Platform and aLaL™ Endotoxin Testing Alternative.
GERMANTOWN, MD August 14, 2025 – MygoGenesis, a next-generation biotechnology stem cell company, today announced the appointment of Deborah Zimmermann as President and Chief Executive Officer. Zimmermann brings over 30 years of progressive leadership experience in the biotechnology and pharmaceutical industries.
Zimmermann joined MygoGenesis in 2022 as Head of Commercial Strategy and Business Development. Prior to this, she held senior leadership roles at Covis Pharma (formerly AMAG Pharmaceuticals), where she redefined the company’s oncology commercial strategy, advanced treatments for iron deficiency anemia (IDA), and supported the transition from a publicly traded company to private ownership under Apollo Global Management. Earlier in her career, Zimmermann spent over two decades at Abbott Laboratories/AbbVie, holding leadership positions across Hospital Products, Diagnostics, Pharmaceuticals, and Nutrition divisions, with expertise in corporate strategy, mergers and acquisitions, and licensing.
“Leading MygoGenesis into its next chapter is a tremendous honor,” said Zimmermann. “We have the science, the vision, and now the commercial momentum to make a lasting impact across life sciences, healthcare, and product safety. MygoGenesis is not only a transformative solution to a longstanding biological challenge, but also a model for how we will deliver ethical, scalable biotech solutions across multiple markets.”
Under Zimmermann’s commercial leadership, MygoGenesis has engaged in multiple licensing discussions with top-tier global biomedical companies. These discussions focus on AmeboGenesis’ lead application: aLaL™, a novel alternative to Limulus Amebocyte Lysate (LAL), the FDA-mandated test for bacterial endotoxins in injectable drugs and medical devices. Unlike conventional LAL production – which relies on extracting blood from endangered horseshoe crabs – aLaL is lab-derived, bio-identical, more sensitive, and virtually unlimited in the scale of amebocyte production. This positions aLaL as the future standard for endotoxin detection, biomedical diagnostics, water filtration, and consumer product safety.
“I couldn’t be more confident in Deborah’s ability to lead us through our next stage of growth,” said Dan Kilbank, Founder and Chief Scientific Officer of MygoGenesis. “Her commercial acumen, strategic vision, and respect for the science make her the perfect leader to bring this platform into broad adoption across both the life science and consumer markets.”
Zimmermann’s appointment marks a strategic shift as MygoGenesis positions itself for commercial growth, mission-aligned partnerships, Seed and Series A funding, and non-dilutive licensing opportunities.
The Company’s outgoing CEO, Dr. Art Sagoskin, will take on the newly created role of Chief Scientific Development Officer to focus on scientific innovation and platform expansion.
About MygoGenesis
MygoGenesis is an innovative biotechnology company developing next-generation stem cell technologies and sustainable biomedical solutions. Its AmeboGenesis platform offers lab-derived, scalable, and bio-identical alternatives to traditional bioproducts, addressing critical needs in product safety, diagnostics, and environmental sustainability. MygoGenesis is committed to ethical innovation that transforms traditional markets and improves lives globally.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements related to MygoGenesis’ business strategy, product development, commercialization plans, and funding prospects. Actual results may differ materially due to various factors, including regulatory approvals, market acceptance, competition, and other risks detailed in MygoGenesis’ filings and disclosures. The company undertakes no obligation to update these statements except as required by law.
For more information, visit www.mygogenesis.com and www.amebogenesis.com.
Media Contact
Eric Tulin – Corporate Communications
eric.tulin@mygogenesis.com
(844) 327-4953 ext. 707
A Revolutionary Breakthrough in Biomedical Testing: AmeboGenesis Introduces Sustainable Amebocyte Production for LAL Testing to Detect Bacterial Contamination
Limulus Amebocyte Lysate (LAL) Can Now Be Produced Without Harvesting the Blood of ~800,000 Horseshoe Crabs Each Year, Which Will Help Restore Their Natural Population
GERMANTOWN, Md., March 26, 2024 (Newswire.com) – AmeboGenesis™ has achieved a significant milestone with the introduction of a sustainable Amebocyte production process. This innovative technology produces bio-identical Amebocytes necessary for the production of LAL for medical endotoxin testing without the need for harvesting horseshoe crab blood. The blood of horseshoe crabs, a source of Limulus Amebocyte Lysate (LAL), is a critical component in ensuring the safety of injectable drugs, vaccines, and implantable devices worldwide. The traditional method of obtaining LAL involves the harvesting and bleeding of ~800,000 horseshoe crabs annually, with a survival rate post-harvest that raises concerns for the horseshoe crabs’ survival as a potential endangered species. Read more.
Image Source via Business Insider.